SLC5A2 and Hypertension: Zhang et al. [56] systematically evaluated the clinical efficacy and safety of SGLT-2 inhibitors in patients with T2DM and hypertension by collecting previously published randomized controlled trials (RCTs) to provide data justifying the use of SGLT-2 inhibitors as an adjuvant in the first-line antihypertensive regimen in patients with T2DM and hypertension.